Condition

Metastatic Invasive Breast Cancer

ClinicalTrials.gov condition label

Clinical trials6

Recruiting1

Common interventions11

Lead sponsors shown5

Clinical trials

6 shown

Diagnostic Prediction Model for De Novo Metastatic Breast CancerNCT07752238 · 2026-08-10

Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast CancerNCT07729046 · 2027-07-01

NOT_YET_RECRUITING

Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.NCT07717450 · 2026-09-25

NOT_YET_RECRUITING

Promoting Active Living Among People With Advanced CancerNCT07238023 · 2026-02-27

ACTIVE_NOT_RECRUITING

Self-Acceptance and Supportive Accountability for Active Living Among Adults Receiving ChemotherapyNCT07819045 · 2025-09-10

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast CancerNCT02448771 · 2015-07-09

Common interventions

Acceptance- and Mindfulness-Based InterventionBEHAVIORAL1 Acceptance- and mindfulness-based physical activity promotionBEHAVIORAL1 BazedoxifeneDRUG1 CDK4/6 + Endocrine therapyDRUG1 Completion of Quality-of-life questionnairesOTHER1 ECGPROCEDURE1 Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrantDRUG1 Neratinib + endocrine therapyDRUG1 PalbociclibDRUG1 Tumor assessmentPROCEDURE1 Visual Acuity assessmentPROCEDURE1

Leading sponsors

University of Oklahoma2 Dana-Farber Cancer Institute1 Markusovszky University Teaching Hospital os County Vas1 UNICANCER1 University of California, San Diego1

Trial status mix

COMPLETED2

NOT_YET_RECRUITING2

ACTIVE_NOT_RECRUITING1

RECRUITING1

Phase mix

NA2

PHASE22

PHASE11

PHASE31

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.